Trial Profile
A phase II study of sunitinib (Sutent) in patients with muscle-invasive locally advanced TCC [transitional cell carcinoma] of the bladder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 14 Jun 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 14 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 May 2012 Planned end date changed from 1 Sep 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.